The purpose of this study is to evaluate the efficacy and safety of Lyrica in Indian patients with nerve pain
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
112
Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Bangalore, Karnataka / India, India
Pfizer Investigational Site
Mumbai, Maharashtra, India
Pfizer Investigational Site
Maharashtra, Mumbai, India
Change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) visual analog score (VAS)
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in weekly mean pain scores
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in Euro Quality of Life Questionnaire (EQ-5D) scores
Time frame: End of treatment
Adverse events and laboratory value changes
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in weekly mean sleep interference score
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in sensory, affective, and total components of the pain descriptor score and the Present Pain Intensity (PPI) of the SF-MPQ
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in Patient Global Impression of Change (PGIC)
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in Clinical Global Impression of Change (CGIC)
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in pain interference scores on the Brief Pain Inventory (BPI ) Short-Form
Time frame: End of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Chennai, Tamil Nadu, India
Pfizer Investigational Site
Chennai, Tamil Nadu, India